Circulating Concentrations of the Novel Adipokine Chemerin Are Associated with Cardiovascular Disease Risk in Rheumatoid Arthritis

Patrick H. Dessein, Linda Tsang, Angela J. Woodiwiss, Gavin R. Norton, and Ahmed Solomon

ABSTRACT. Objective. Depending on physiological context, the adipokine chemerin can reduce or enhance cardiovascular risk. We investigated whether chemerin concentrations represent cardiovascular disease risk in rheumatoid arthritis (RA).

Methods. We assessed ELISA-determined chemerin concentrations and those of 4 early endothelial activation molecules as well as angiopoietin 2, which mediates angiogenesis and thereby contributes to advanced atherosclerosis, the common carotid artery intima-media thickness (cIMT), and carotid artery plaque by ultrasound in 236 patients (114 black and 122 white) with RA. Relationships were identified in potential confounder and mediator-adjusted mixed regression models.

Results. Mean (SD) chemerin and median (interquartile range) angiopoietin 2 concentrations were 114 (35) ng/ml and 2560 (2044–3341) pg/ml, respectively; the mean (SD) cIMT was 0.708 (0.110) mm, and 40.3% of patients had plaque. Chemerin concentrations were not related to those of early endothelial activation molecules, but associated with those of angiopoietin 2 [β(SE) = 0.002 (0.0004), p < 0.0001] and plaque [OR 1.006 (95% CI 1.00–1.013), p = 0.05] in all patients. The presence of major conventional cardiovascular risk factors, generalized and abdominal obesity, and RA severity markers modified the independent chemerin-cardiovascular risk relations (interaction p < 0.05).

Consequently, chemerin concentrations were associated with cIMT in those with but not without overweight or generalized obesity and abdominal obesity [β(SE) = 0.001 (0.0003), p = 0.005 and 0.001 (0.0001), p = 0.001 vs –0.001 (0.0004), p = 0.2 and –0.0002 (0.0004), p = 0.6, respectively], and with plaque in those without but not with generalized obesity [OR 1.008 (95% CI) 1.00–1.016, p = 0.03 vs 1.003 (0.990–1.017), p = 0.6, respectively]. The β (SE) for the chemerin-intima-media thickness relations in patients with overweight or generalized obesity and abdominal obesity were larger than in those without these characteristics (p < 0.0001 and = 0.04, respectively).

Conclusion. Chemerin is associated with endothelial activation and atherosclerosis in RA. Adiposity influences the chemerin-atherosclerotic phenotype relations in RA. (First Release July 15 2014; J Rheumatol 2014;41:1746–54; doi:10.3899/jrheum.140122)

Key Indexing Terms:
RHEUMATOID ARTHRITIS                                         CARDIOVASCULAR RISK
ENDOTHELIAL ACTIVATION                                        OBESITY
CHEMERIN

Rheumatoid arthritis (RA) predisposes substantially to traditional and nontraditional risk factor dependent atherosclerotic cardiovascular disease (CVD) with a prevalence and incidence as large as in diabetes.1,2,3. Atherogenesis in RA remains poorly understood, and currently recommended cardiovascular risk strategies have potentially important shortcomings.5,6. It is against this background that the need for identifying novel biomarkers of cardiovascular risk in this inflammatory disease has been emphasized5,6.

Chemerin, also known as tazarotene-induced gene 2 or retinoic acid receptor responder 2, was originally identified as a gene upregulated in psoriatic skin by the synthetic retinoid tazarotene in 1997. In 2007, chemerin was identified as a novel adipokine that regulates adipogenesis and adipocyte metabolism.7 Chemerin is a natural ligand and chemotactic signal for cells expressing G protein-coupled receptor chemokine-like receptor 17,8.

A large body of evidence derived from mechanistic and clinical studies indicates that chemerin is proinflammatory and implicated in metabolic risk.7,8. As an early biomarker of metabolic and inflammatory disease, chemerin concentrations predicted incident metabolic risk more strongly than
measures of insulin resistance and leptin concentrations in a population without clinical symptoms of metabolic syndrome. Chemerin also induces the production of E-selectin and intercellular adhesion molecule 1 (ICAM-1) in endothelial cells, and further increases angiogenesis, which contributes to advanced atherosclerosis by augmenting plaque development and destabilization. Importantly, in the present context, chemerin participates in normal physiological processes and also exhibits protective properties in that, depending on (patho)physiological status, it can have anti-inflammatory activity, and both reduced and elevated chemerin signaling may cause aberrant glucose metabolism. Therefore, disease status and severity require consideration upon evaluating the biological effects of chemerin.

As applies to other adipokines, chemerin is involved in the pathophysiology of RA. Chemerin is expressed in synovial endothelial, lining, and sublining cells, and its production is upregulated by tumor necrosis factor-α (TNF-α) and interferon-γ in RA; chemerin stimulated the production of interleukin 6 (IL-6), chemokine (C-C motif) ligand 2, Toll-like receptor 4 mRNA, and matrix metalloproteinase 3 by fibroblast-like synoviocytes.

Adipokines other than chemerin are linked to metabolic risk, early endothelial activation, and inflammation in RA. Chemerin is involved in the pathophysiology of RA. Chemerin is expressed in synovial endothelial, lining, and sublining cells, and its production is upregulated by tumor necrosis factor-α (TNF-α) and interferon-γ in RA; chemerin stimulated the production of interleukin 6 (IL-6), chemokine (C-C motif) ligand 2, Toll-like receptor 4 mRNA, and matrix metalloproteinase 3 by fibroblast-like synoviocytes.

**Adipokines other than chemerin** are linked to metabolic risk, early endothelial activation, and inflammation in RA. Chemerin is involved in the pathophysiology of RA. Chemerin is expressed in synovial endothelial, lining, and sublining cells, and its production is upregulated by tumor necrosis factor-α (TNF-α) and interferon-γ in RA; chemerin stimulated the production of interleukin 6 (IL-6), chemokine (C-C motif) ligand 2, Toll-like receptor 4 mRNA, and matrix metalloproteinase 3 by fibroblast-like synoviocytes.

**Adipokines other than chemerin** are linked to metabolic risk, early endothelial activation, and inflammation in RA. Chemerin is involved in the pathophysiology of RA. Chemerin is expressed in synovial endothelial, lining, and sublining cells, and its production is upregulated by tumor necrosis factor-α (TNF-α) and interferon-γ in RA; chemerin stimulated the production of interleukin 6 (IL-6), chemokine (C-C motif) ligand 2, Toll-like receptor 4 mRNA, and matrix metalloproteinase 3 by fibroblast-like synoviocytes.

**Adipokines other than chemerin** are linked to metabolic risk, early endothelial activation, and inflammation in RA. Chemerin is involved in the pathophysiology of RA. Chemerin is expressed in synovial endothelial, lining, and sublining cells, and its production is upregulated by tumor necrosis factor-α (TNF-α) and interferon-γ in RA; chemerin stimulated the production of interleukin 6 (IL-6), chemokine (C-C motif) ligand 2, Toll-like receptor 4 mRNA, and matrix metalloproteinase 3 by fibroblast-like synoviocytes.

**Adipokines other than chemerin** are linked to metabolic risk, early endothelial activation, and inflammation in RA. Chemerin is involved in the pathophysiology of RA. Chemerin is expressed in synovial endothelial, lining, and sublining cells, and its production is upregulated by tumor necrosis factor-α (TNF-α) and interferon-γ in RA; chemerin stimulated the production of interleukin 6 (IL-6), chemokine (C-C motif) ligand 2, Toll-like receptor 4 mRNA, and matrix metalloproteinase 3 by fibroblast-like synoviocytes.

**Adipokines other than chemerin** are linked to metabolic risk, early endothelial activation, and inflammation in RA. Chemerin is involved in the pathophysiology of RA. Chemerin is expressed in synovial endothelial, lining, and sublining cells, and its production is upregulated by tumor necrosis factor-α (TNF-α) and interferon-γ in RA; chemerin stimulated the production of interleukin 6 (IL-6), chemokine (C-C motif) ligand 2, Toll-like receptor 4 mRNA, and matrix metalloproteinase 3 by fibroblast-like synoviocytes.

**Adipokines other than chemerin** are linked to metabolic risk, early endothelial activation, and inflammation in RA. Chemerin is involved in the pathophysiology of RA. Chemerin is expressed in synovial endothelial, lining, and sublining cells, and its production is upregulated by tumor necrosis factor-α (TNF-α) and interferon-γ in RA; chemerin stimulated the production of interleukin 6 (IL-6), chemokine (C-C motif) ligand 2, Toll-like receptor 4 mRNA, and matrix metalloproteinase 3 by fibroblast-like synoviocytes.

**Adipokines other than chemerin** are linked to metabolic risk, early endothelial activation, and inflammation in RA. Chemerin is involved in the pathophysiology of RA. Chemerin is expressed in synovial endothelial, lining, and sublining cells, and its production is upregulated by tumor necrosis factor-α (TNF-α) and interferon-γ in RA; chemerin stimulated the production of interleukin 6 (IL-6), chemokine (C-C motif) ligand 2, Toll-like receptor 4 mRNA, and matrix metalloproteinase 3 by fibroblast-like synoviocytes.

**Adipokines other than chemerin** are linked to metabolic risk, early endothelial activation, and inflammation in RA. Chemerin is involved in the pathophysiology of RA. Chemerin is expressed in synovial endothelial, lining, and sublining cells, and its production is upregulated by tumor necrosis factor-α (TNF-α) and interferon-γ in RA; chemerin stimulated the production of interleukin 6 (IL-6), chemokine (C-C motif) ligand 2, Toll-like receptor 4 mRNA, and matrix metalloproteinase 3 by fibroblast-like synoviocytes.

**Adipokines other than chemerin** are linked to metabolic risk, early endothelial activation, and inflammation in RA. Chemerin is involved in the pathophysiology of RA. Chemerin is expressed in synovial endothelial, lining, and sublining cells, and its production is upregulated by tumor necrosis factor-α (TNF-α) and interferon-γ in RA; chemerin stimulated the production of interleukin 6 (IL-6), chemokine (C-C motif) ligand 2, Toll-like receptor 4 mRNA, and matrix metalloproteinase 3 by fibroblast-like synoviocytes.

**Adipokines other than chemerin** are linked to metabolic risk, early endothelial activation, and inflammation in RA. Chemerin is involved in the pathophysiology of RA. Chemerin is expressed in synovial endothelial, lining, and sublining cells, and its production is upregulated by tumor necrosis factor-α (TNF-α) and interferon-γ in RA; chemerin stimulated the production of interleukin 6 (IL-6), chemokine (C-C motif) ligand 2, Toll-like receptor 4 mRNA, and matrix metalloproteinase 3 by fibroblast-like synoviocytes.
Data management analysis. Dichotomous variables are expressed as proportions or percentages, and continuous variables as mean (SD) or median (interquartile range) when non-normally distributed. Non-normally distributed characteristics were also logistically transformed prior to their inclusion in multivariable statistical analysis. An endothelial activation score was used to provide a summary measure of early endothelial activation and was calculated from SD (z) scores as follows: 
\[ z(\text{selectin}) + z(\text{VCAM-1}) + z(\text{ICAM-1}) + z(\text{MCP-1}) \]

Associations of age at disease onset or at the time of the study, and sex and population grouping with chemerin concentrations were assessed by entering the respective characteristics together in single mixed regression models. Associations of other baseline characteristics with chemerin concentrations were evaluated in models with adjustment for demographic characteristics that included age at the time of the study and not age at disease onset, because the latter was not related to chemerin concentrations.

The independent relations of chemerin concentrations with metabolic risk factors were assessed in demographic characteristic, waist circumference, GFR, leflunomide (LEF) and TNF-α blockade use (potential confounders or/and determinants identified in previous analysis), and cardiovascular drug use adjusted mixed linear regression models. The independent relations of chemerin concentrations with endothelial activation, cIMT, and plaque were determined in Framingham score (calculated from age, sex, and major conventional risk factors), race, waist, GFR, CRP, and leptin concentrations, and LEF and TNF-α blockade use adjusted mixed (linear or logistic as appropriate) regression models.

Patients with RA who experience conventional risk factors or severe disease are reportedly at high risk of CVD. For these reasons, together with the dependence of chemerin effects on physiological context and our recent experience with adipokine metabolism in RA, we assessed the effect of patient characteristics on chemerin-cardiovascular risk relations by adding interaction terms to the models, and stratified analysis when indicated (significant interaction p values), that is, in subgroups with and without patient characteristics of interest in the present context. For this purpose, patients with BMI of ≥30 kg/m² and those who met the National Cholesterol Education Program for metabolic syndrome waist criterion were considered to sustain overall and abdominal obesity, respectively. When appropriate, patients were categorized in subgroups based on means. In view of the small number of patients who were RF-positive or had extrarticular features, sensitivity analysis in subgroups based on the presence or absence of these characteristics was not performed.

Statistical computations were made using the GB Stat program (Dynamic Microsystems Inc.) and SAS software, version 9.1 (The SAS Institute). Significance was set at p ≤ 0.05.

RESULTS
Descriptive statistics of the recorded characteristics are given in Table 1. The mean (SD) Framingham score was 5 (7), as determined using an algorithm. However, this characteristic was non-normally distributed with a median (interquartile range) value of only 2 (1–6). All patients were using synthetic disease-modifying agents and only 1 of them used a biologic agent other than TNF-α blockade (rituximab).

Associations of baseline characteristics with chemerin concentrations. As presented in Table 2, demographic characteristics, anthropometric measures, the use of antihypertensives, disease activity, and the GFR were each significantly associated with chemerin concentrations. Among the disease activity variables, CRP concentrations were most strongly related to chemerin concentrations. LEF and TNF-α blockade use were also borderline related to chemerin concentrations (p = 0.06 and 0.1, respectively), and hence additionally included as potential confounders in subsequent analyses. In separate analysis, when BMI and waist were entered into the same demographic characteristic and GFR-adjusted model, only waist circumference remained associated with chemerin concentrations, the DAS28 and waist were related to chemerin concentrations independent of one another, and the antihypertensive agent use-chemerin concentrations relation was explained by abdominal adiposity (data not shown). In view of these results, waist circumference was the anthropometric measure that was included in subsequent models. All cardiovascular drug use was consistently forced into the models in which chemerin-cardiovascular risk relations were evaluated.

Independent relationships of chemerin concentrations with metabolic risk. As also shown in Table 2, in all 236 patients, chemerin concentrations were independently related to those of leptin. Chemerin levels were not related to any of the other metabolic risk factors.

An RA duration of > 10 years affected the chemerin-HDL cholesterol concentration and chemerin-cholesterol-HDL cholesterol ratio associations (interaction p = 0.04 and 0.006, respectively). The presence of deformed joints affected the chemerin-systolic, -diastolic, and -mean blood pressure relations (interaction p = 0.01, 0.03, and 0.01, respectively). In stratified analysis, chemerin concentrations were independently associated with systolic blood pressure, diastolic blood pressure, mean blood pressure, and cholesterol-HDL-cholesterol ratio in patients with but not in those without a disease duration of > 10 years [β (SE) = 0.117 (0.056), p = 0.03, 0.068 (0.033), p = 0.04, 0.100 (0.045), p = 0.03 and 0.006 (0.005), p = 0.03 vs –0.031 (0.078), p = 0.7, –0.050 (0.043), p = 0.2, –0.038 (0.062), p = 0.5 and 0.001 (0.004), p = 0.7, respectively], and with systolic and diastolic blood pressure in patients with but not in those without deformed joints [β (SE) = 0.111 (0.056), p = 0.05 and 0.090 (0.046), p = 0.05 vs –0.089 (0.071), p = 0.2 and –0.072 (0.057), p = 0.2, respectively].

Generalized obesity affected the chemerin-leptin and chemerin-retinol binding protein 4 concentration relations (interaction p = 0.02 and 0.03, respectively); abdominal obesity affected on the chemerin-adenocin concentration association (interaction p = 0.03). In stratified analysis, chemerin concentrations were related to leptin levels in patients without but not in those with generalized and abdominal obesity [β (SE) = 0.003 (0.001), p = 0.0008 and 0.003 (0.001), p = 0.02 vs –0.001 (0.001), p = 0.5 and 0.001 (0.001), p = 0.2, respectively].

Independent relationships of chemerin concentrations with endothelial activation and atherosclerosis. Table 3 shows that whereas chemerin concentrations were not related to early endothelial activation in all patients, they were
strongly associated with angiopoitin 2 levels. Further, chemerin concentrations were related to cIMT and plaque in univariate and multivariate analysis, respectively. In a separate analysis, the chemerin concentrations-plaque relationship became significant only once leptin levels were added to the model (data not shown).

The presence of major cardiovascular risk factors affected the chemerin-selectin concentration, chemerin-endothelial activation score, and chemerin-plaque relationship (interaction p = 0.05, 0.03, and 0.02, respectively); generalized obesity affected the chemerin-plaque association (interaction p = 0.01); and abdominal obesity affected the chemerin-ICAM-1 and chemerin-cIMT relationship (interaction p = 0.02 and 0.04, respectively).

Table 4 gives results obtained in the related stratified analysis. Chemerin concentrations were related to the endothelial activation score in patients with but not in those without major cardiovascular risk factors, with cIMT in patients that were overweight or obese, and those who sustained abdominal obesity but not in those without these risk factors, and with plaque in patients without but not in those with generalized obesity. The β (SE) for the chemerin-cIMT relations in patients who were overweight or obese and those who experienced abdominal obesity were

---

Table 1. Recorded characteristics in 236 patients with RA. Dichotomous variables are expressed as proportions or percentages and continuous characteristics as mean ± SD or median (interquartile range).

<table>
<thead>
<tr>
<th>Demographic characteristics</th>
</tr>
</thead>
</table>
| Age at disease onset, yrs | 43.5 (13.0)  
| Age at study time, yrs | 57.1 (10.8)  
| Female sex | 83.5  
| Black | 48.3  
| White | 51.7  
| Lifestyle factors |  
| Exercise | 36.8  
| Alcohol use | 20.9  
| Current smoking | 6.8  
| Anthropometry |  
| Body mass index, kg/m² | 27.5 (6.0)  
| Waist circumference, cm | 91.2 (13.4)  
| Waist-hip ratio | 0.86 (80.3–91.3)  
| Cardiovascular agents |  
| Antihypertensives | 48.3  
| Statins | 28.4  
| Ezetimibe | 0.9  
| Oral glucose-lowering agents | 8.9  
| Insulin | 1.7  
| RA characteristics |  
| Disease duration, yrs | 13.6 (9.3)  
| Rheumatoid factor-positive | 75.8  
| Clinical Disease Activity Index | 7.3 (2.0–13.8)  
| Disease Activity Score in 28 joints | 3.9 (1.5)  
| Swollen joints | 1 (0–4)  
| Tender joints | 0 (0–2)  
| Patient disease activity | 3.3 (2.8)  
| Physician disease activity | 1.2 (0.0–3.0)  
| Erythrocyte sedimentation rate, mm/h | 12 (5–27)  
| C-reactive protein, mg/l | 5.3 (2.2–12.5)  
| Interleukin 6, pg/ml | 3.5 (2.2–5.9)  
| Leukocytes, n/ml | 5.9 (4.8–7.6)  
| No. deformed joints | 73.6  
| Extraarticular manifestation | 7.6  
| Synthetic disease-modifying agents |  
| Methotrexate | 84.3  
| Chloroquine | 66.1  
| Leflunomide | 19.7  
| Sulfasalazine | 19.1  
| Azathioprine | 14.8  

RA: rheumatoid arthritis; HDL: high-density lipoprotein; LDL: low-density lipoprotein; VCAM-1: vascular adhesion molecule 1; ICAM-1: intercellular adhesion molecule 1; MCP-1: monocyte chemoattractant protein 1.

---

Table 4 gives results obtained in the related stratified analysis. Chemerin concentrations were related to the endothelial activation score in patients with but not in those without major cardiovascular risk factors, with cIMT in patients that were overweight or obese, and those who sustained abdominal obesity but not in those without these risk factors, and with plaque in patients without but not in those with generalized obesity. The β (SE) for the chemerin-cIMT relations in patients who were overweight or obese and those who experienced abdominal obesity were
Table 2. Significant associations of baseline characteristics with chemerin concentrations and of the latter with metabolic risk factors. The baseline variable–chemerin associations were assessed in demographic characteristics adjusted models. The chemerin-metabolic risk factor relations were evaluated in demographic characteristics as well as waist circumference, glomerular filtration rate, use of leflunomide and tumor necrosis factor-α blockade, cardiovascular drug use, and C-reactive protein concentrations adjusted models.

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>β (SE)</th>
<th>p</th>
<th>β (SE)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Demographic characteristics</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age at study time</td>
<td>0.405 (0.209)</td>
<td>0.05</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female sex</td>
<td>12.5 (6.2)</td>
<td>0.04</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Black</td>
<td>13.5 (4.4)</td>
<td>0.002</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anthropometry</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Body mass index</td>
<td>1.55 (0.39)</td>
<td>&lt; 0.0001</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Waist circumference</td>
<td>0.75 (0.17)</td>
<td>&lt; 0.0001</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiovascular agents</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antihypertensives</td>
<td>12.3 (4.6)</td>
<td>0.009</td>
<td></td>
<td></td>
</tr>
<tr>
<td>RA characteristics</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Disease Activity Score in 28 joints</td>
<td>3.97 (1.51)</td>
<td>0.009</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Physician disease activity*</td>
<td>22.0 (7.8)</td>
<td>0.005</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Erythrocyte sedimentation rate*</td>
<td>19.0 (5.2)</td>
<td>0.0003</td>
<td></td>
<td></td>
</tr>
<tr>
<td>C-reactive protein*</td>
<td>22.3 (4.0)</td>
<td>&lt; 0.0001</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leukocytes*</td>
<td>43.2 (15.3)</td>
<td>0.005</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glomerular filtration rate*</td>
<td>−57.4 (17.9)</td>
<td>0.002</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Metabolic risk factors</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adipokines</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leptin*</td>
<td>0.002 (0.001)</td>
<td>0.008</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Logarithmically transformed variables. β: regression coefficient; SE: standard error; RA: rheumatoid arthritis.

larger than in those without these characteristics (p < 0.0001 and 0.04, respectively). Chemerin concentrations were consistently associated with those of angiopoietin 2 among subgroups.

In the models shown in Table 4, we adjusted for the Framingham score, which includes age. Nevertheless, the confounding effect of age may have been underestimated. When we replaced the Framingham score by age, sex, hypertension, dyslipidemia, smoking, and diabetes, the chemerin-cIMT relationship remained significant in patients with generalized obesity, overweight, or generalized obesity and abdominal obesity [β (SE) = 0.001 (0.0004), p = 0.01, 0.001 (0.0003), p = 0.02 and 0.001 (0.0003), p = 0.002, respectively]. This approach was not to be used for chemerin-plaque relations because it would have meant using overfitted logistic regression models, which can give false-positive or false-negative results.

DISCUSSION

In this RA study, chemerin concentrations were consistently and independently associated with those of angiopoietin 2, which contributes relevantly to angiogenesis, and hence is an endothelial activation of advanced rather than early atherosclerosis. Angiopoietin 2 concentrations are related to prevalent and incident CVD in RA.

Chemerin concentrations were also independently associated to carotid artery plaque in all patients. Interestingly, this relationship was leptin-driven, and hence suggests a combined effect of leptin and chemerin in atherosclerosis among patients with RA. However, our most striking finding was that the presence of major conventional cardiovascular risk factors, excess abdominal and generalized adiposity, and RA severity markers consistently modified the independent chemerin-cardiovascular risk relations. This translated into associations of chemerin concentrations with cIMT in patients who were overweight or had generalized obesity and those who experienced abdominal obesity, and with carotid artery plaque in patients who were normal or overweight.

Table 3. Relationships of chemerin concentrations with endothelial activation and carotid atherosclerosis in 236 patients. Framingham score, race, waist circumference, glomerular filtration rate, leflunomide and tumor necrosis factor-α blockade use, and C-reactive protein and leptin concentrations were adjusted for in multivariate models. Significant association is shown in bold.

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Univariate</th>
<th>p</th>
<th>Multivariate</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Endothelial activation</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Early</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>E-selectin</td>
<td>0.059 (0.036)</td>
<td>0.1</td>
<td>0.012 (0.042)</td>
<td>0.8</td>
</tr>
<tr>
<td>VCAM-1*</td>
<td>0.0004 (0.0003)</td>
<td>0.1</td>
<td>0.0004 (0.0003)</td>
<td>0.2</td>
</tr>
<tr>
<td>ICAM-1*</td>
<td>−0.0004 (0.0003)</td>
<td>0.2</td>
<td>−0.0001 (0.0004)</td>
<td>0.7</td>
</tr>
<tr>
<td>MCP-1*</td>
<td>0.001 (0.001)</td>
<td>0.09</td>
<td>0.001 (0.001)</td>
<td>0.1</td>
</tr>
<tr>
<td>Early endothelial activation score</td>
<td>0.007 (0.004)</td>
<td>0.1</td>
<td>0.006 (0.005)</td>
<td>0.2</td>
</tr>
<tr>
<td>Angiopoietin 2*</td>
<td>0.002 (0.0004)</td>
<td>&lt; 0.0001</td>
<td>0.002 (0.0004)</td>
<td>0.0002</td>
</tr>
<tr>
<td>Atherosclerosis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intima-media thickness</td>
<td>0.0005 (0.0002)</td>
<td>0.02</td>
<td>0.0004 (0.0002)</td>
<td>0.1</td>
</tr>
<tr>
<td>OR (95% CI)</td>
<td>p</td>
<td></td>
<td>OR (95% CI)</td>
<td>p</td>
</tr>
<tr>
<td>Plaque</td>
<td>1.005 (0.999–1.011)</td>
<td>0.08</td>
<td>1.006 (1.001–1.013)</td>
<td>0.05</td>
</tr>
</tbody>
</table>

*Logarithmically transformed. β: regression coefficient; SE: standard error; VCAM-1: vascular adhesion molecule 1; ICAM-1: intercellular adhesion molecule 1; MCP-1: monocyte chemoattractant protein 1.
Atherosclerosis in RA. Also, the INTERHEART study investigators found that the waist-hip ratio was more strongly associated with myocardial infarction than was BMI, whereas in a large study performed in Finland and reported by Hu, et al., BMI but not waist-hip ratio enhanced the risk of stroke in women. Notably, coronary artery but not cerebrovascular event rates were included as outcome characteristics in the Maradit Kremers, et al study.

In our previous investigation on adiposity and atherosclerosis in RA, the relationships of BMI with cIMT and waist-hip ratio with plaque were explained by metabolic risk factors. Conversely, in our current study, the independent relationship between chemerin and atherosclerosis in both obese and nonobese participants was not explained by metabolic risk factors, as well as several other potential mediators and confounding characteristics. Taken together, our findings indicate that chemerin represents CVD risk in both obese and nonobese patients with RA. Additionally, our results suggest that chemerin may contribute to the link between inflammation and increased risk of coronary artery disease among nonobese patients with RA. Indeed, systemic inflammation was strongly associated with chemerin concentrations in our analysis, and suppression of inflammation with adalimumab is linked to reduced chemerin concentrations in RA.

Importantly in the present context, cIMT and plaque are different phenotypes of atherosclerosis, and biologically and genetically distinct. Intima-media thickening reflects mostly an enlarged tunica media due to an adapted response to aging and particularly blood pressure, and is related to stroke risk factors and prevalence. By contrast, carotid plaque develops because of intimal pathology and represents advanced atherosclerosis that is more closely linked to coronary artery disease risk factors and prevalence. We have documented that BMI or generalized adiposity associates independently with blood pressure and cIMT, whereas anthropometric measures of abdominal adiposity are related to lipids and carotid artery plaque in women with intensively managed RA. Thus, BMI and the waist-hip ratio are associated with different metabolic risk factor profiles and reflect different aspects of atherosclerosis in RA. Also, the INTERHEART study investigators found that the waist-hip ratio was more strongly associated with myocardial infarction than was BMI, whereas in a large study performed in Finland and reported by Hu, et al., BMI but not waist-hip ratio enhanced the risk of stroke in women. Notably, coronary artery but not cerebrovascular event rates were included as outcome characteristics in the Maradit Kremers, et al study.

Table 4. Independent relationships of chemerin concentrations (range = 2 to 282 ng/ml) with endothelial activation and atherosclerosis in subgroups. Framingham score, race, waist circumference, glomerular filtration rate, leflunomide and tumor necrosis-α blockade use, and C-reactive protein and leptin concentrations were adjusted for in each model. Significant associations are shown in bold.

<table>
<thead>
<tr>
<th>Subgroups ≥ 1 major CVRF</th>
<th>Endothelial Activation Score β (SE)</th>
<th>p</th>
<th>Angiopoietin 2 Concentrations β (SE)</th>
<th>p</th>
<th>Intima-Media Thickness β (SE)</th>
<th>p</th>
<th>Plaque OR (95% CI)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes, n = 162</td>
<td>0.011 (0.006)</td>
<td>0.04</td>
<td>0.001 (0.0004)</td>
<td>0.006</td>
<td>0.0004 (0.0003)</td>
<td>0.08</td>
<td>1.008 (0.999–1.098)</td>
<td>0.06</td>
</tr>
<tr>
<td>No, n = 66</td>
<td>0.0007 (0.0007)</td>
<td>0.3</td>
<td>0.002 (0.001)</td>
<td>0.001</td>
<td>0.0002 (0.0005)</td>
<td>0.4</td>
<td>1.005 (0.988–1.022)</td>
<td>0.5</td>
</tr>
<tr>
<td>Missing, n = 8</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Obesity</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes, n = 70</td>
<td>0.001 (0.009)</td>
<td>0.9</td>
<td>0.002 (0.001)</td>
<td>0.007</td>
<td>0.001 (0.0003)</td>
<td>0.008</td>
<td>1.003 (0.990–1.017)</td>
<td>0.6</td>
</tr>
<tr>
<td>No, n = 161</td>
<td>0.007 (0.007)</td>
<td>0.3</td>
<td>0.002 (0.001)</td>
<td>0.001</td>
<td>0.0001 (0.0003)</td>
<td>0.7</td>
<td>1.008 (1.000–1.016)</td>
<td>0.03</td>
</tr>
<tr>
<td>Missing, n = 5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Overweight or obese</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes, n = 138</td>
<td>0.004 (0.007)</td>
<td>0.5</td>
<td>0.002 (0.001)</td>
<td>0.005</td>
<td>0.001 (0.0003)</td>
<td>0.005</td>
<td>1.006 (0.997–1.015)</td>
<td>0.2</td>
</tr>
<tr>
<td>No, n = 93</td>
<td>0.009 (0.010)</td>
<td>0.4</td>
<td>0.001 (0.001)</td>
<td>0.02</td>
<td>−0.001 (0.0004)</td>
<td>0.2</td>
<td>1.005 (0.995–1.016)</td>
<td>0.3</td>
</tr>
<tr>
<td>Missing, n = 5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MetS waist</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes, n = 105</td>
<td>−0.004 (0.008)</td>
<td>0.6</td>
<td>0.001 (0.001)</td>
<td>0.01</td>
<td>0.001 (0.0001)</td>
<td>0.001</td>
<td>1.005 (0.995–1.016)</td>
<td>0.3</td>
</tr>
<tr>
<td>No, n = 128</td>
<td>0.013 (0.008)</td>
<td>0.09</td>
<td>0.002 (0.001)</td>
<td>0.007</td>
<td>−0.0002 (0.0004)</td>
<td>0.6</td>
<td>1.009 (0.999–1.018)</td>
<td>0.06</td>
</tr>
<tr>
<td>Missing, n = 3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

β: regression coefficient; SE: standard error; CVRF: cardiovascular risk factors (hypertension, dyslipidemia, smoking, and diabetes); MetS: metabolic syndrome.
overproduced in RA and can induce the production of retinoic acid. The potential role of chemerin derived from endothelial cell activation in atherogenesis merits further study.

Among patients with major conventional risk factors, chemerin was associated not only with angiotensin 2 concentrations, but also with surrogate markers of early endothelial activation in our study. These patients also had an increased OR for plaque, but this did not reach significance (p = 0.06). The presence of major conventional risk factors also modifies the potential effects of resistin on surrogate markers of early endothelial activation in RA.

RA severity additionally affected the chemerin-conventional metabolic risk relations, but in contrast to findings on resistin in atherogenesis, disease severity modified neither the chemerin-endothelial activation associations nor the chemerin-atherosclerosis relation. Leptin is an adiposity marker in RA, and in our study, both leptin and chemerin concentrations were higher in obese compared to nonobese patients (data not shown). Reminiscent of the paradoxical effect of adiposity on cardiovascular risk, we found that chemerin concentrations are independently related to those of leptin in nonobese rather than obese patients. Whereas chemerin concentrations reportedly predict metabolic risk development in patients without RA, we did not find an association of chemerin concentrations with prevalent conventional metabolic risk factors.

A recent South Korean study performed in patients with RA revealed that disease activity rather than obesity was associated with chemerin concentrations in RA. We found that disease activity and adiposity were related to chemerin concentrations independent of one another. We also showed that chemerin concentrations are higher in African black patients compared to white patients with RA. In this regard, we previously reported that both the production and biological effects of adipokines can differ by population or ethnic origin in RA.

Besides angiotensin 2 concentrations, we assessed the production of 4 endothelial activation molecules that mediate the initial stages of atherosclerosis, and were shown to be strongly upregulated and associated with prevalent and incident atherosclerosis in RA. CIMT and carotid artery plaque that were our main outcome measures independently predicted incident cardiovascular events in patients with RA and patients without RA.

Our study has limitations. Conceptually, endothelial activation marker concentrations can represent disease activity. The chemerin-endothelial activation relationship identified in the present investigation were independent of disease activity variables. Our cross-sectional study design precludes drawing inferences on the direction of causality. Circulating CRP concentrations are determined not only by disease activity, but also by insulin resistance in RA, and those of chemerin do not necessarily represent its tissue levels. We did not include markers of insulin resistance such as the homeostasis model assessment of insulin resistance, which could have been informative in the present context. The standard z-score of endothelial activation as used in our study was previously reported by us, but nevertheless awaits external validation.

Contrary to other investigated adipokines, apart from retinol binding protein 4, chemerin relates not only to surrogate markers of endothelial activation, but also atherosclerosis in RA. Chemerin represents CVD risk and adiposity influences the chemerin-atherosclerotic phenotype relations in RA. Additional longitudinal studies are needed to fully determine the role of chemerin concentrations in cardiovascular risk stratification in RA.

ACKNOWLEDGMENT
We thank Belinda A. Stevens for performing carotid ultrasound examinations in 104 of the study participants.

REFERENCES


33. Johnsen SH, Mathiesen EB. Carotid plaque compared with intima-media thickness as a predictor of coronary and cardiovascular risk.


